| DDR | DNA damage response |
| FDA | Food and Drug Administration (United States) |
| HAT | Histone acetyltransferase |
| HATi | HAT inhibitors |
| HDAC | Histone de-acetyltransferase |
| HDACi | Histone de-acetyltransferase inhibitor |
| HMT | Histone methyltransferases |
| KDM | Lysine demethylases |
| DSB | Double strand break |
| SSB | Single Strand Break |
| SSA | Single Strand Annealing |
| HR | Homologous recombination |
| NHEJ | Non-Homologous End Joining |
| CA | Centrosome Amplification |
| PARPi | PARP inhibitors |
| ATM | Ataxia-telangiectasia mutated |
| ATR | Ataxia and Rad3-related |
| PIKK | Phosphatidylinositol 3-kinase-related kinase |
| IR | Ionizing radiation |
| FA | Fanconi Anemia |
| MMC | Mitomycin C |
| MMEJ | Microhomology-Mediated End Joining |
| PTM | Post translational modifications |